NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02763579,A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC),https://clinicaltrials.gov/study/NCT02763579,IMpower133,COMPLETED,"This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.",YES,Small Cell Lung Carcinoma,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Placebo","Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population, Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least 20% increase in the sum of the longest diameter of target lesions compared to baseline, or unequivocal progression in non-target lesion(s), or the appearance of new lesion(s)., Baseline until PD or death, whichever occurs first (up to approximately 23 months)|Duration of Overall Survival (OS) in the Global Population, OS is defined as the time from randomization to death from any cause., Baseline until death from any cause (up to approximately 23 months)","Percentage of Participants With Objective Response Rate (ORR) as Assessed by the Investigator Using RECIST v1.1 in the Global Population, Objective response (OR) is defined as complete response (CR) or partial response (PR) as determined by the investigator according to RECIST v1.1., Baseline until partial response (PR) or complete response (CR), whichever occurs first (up to approximately 23 months)|Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 in the Global Population, DOR is defined as the time interval from first occurrence of a documented objective response to the time of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever comes first., First occurrence of PR or CR until PD or death, whichever occurs first (up to approximately 23 months)|PFS Rate at 6 Months and at 1 Year in Global Population, PFS rates at 6 months and at 1 year is defined as the proportion of participants who are alive without disease progression 6 months and 1 year after randomization, respectively., 6 months, 1 year|OS Rate at 1 Year and 2 Years in the Global Population, OS rates at 1 and 2 years is defined as the proportion of participants who are alive 1 year and 2 years after randomization, respectively., 1 year, 2 years|Time to Deterioration (TTD) Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30) and Supplemental Lung Cancer Module (QLQ-LC13) in the Global Population, TTD according to the EORTC QLQ-C30 and EORTC QLQ-LC13 measures were evaluated in each of the following linearly transformed symptom scores: cough, dyspnea (single item), dyspnea (multi-item subscale), chest pain, or arm/shoulder pain. The linear transformation gives each individual symptom subscale a possible score of 0 to 100. For the symptom to be considered ""deteriorated,"" a score increase of ≥10 points above baseline must be held for at least two consecutive assessments or an initial score increase of ≥10 points is followed by death within 3 weeks from the last assessment. A ≥ 10-point change in the symptoms subscale score is perceived by participants as clinically significant., Baseline until deterioration per symptom subscale (up to approximately 23 months)|Percentage of Participants With at Least One Adverse Event in the Global Population, The percentage of participants with at least one adverse event in the global population., Baseline until up to 90 days after end of treatment (up to approximately 49 months)|Percentage of Participants With Anti-Drug Antibodies (ADA) to Atezolizumab in the Global Population, The baseline prevalence and post-baseline incidence of ADAs against atezolizumab., Predose (0 hours [H]) on Day (D) 1 of Cycles (C) 1, 2, 3, 4, 8, 16, and every 8 cycles (Q8C) thereafter (cycle = 21 days) until treatment discontinuation (up to 23 months) and 120 days after last dose (up to approximately 23 months overall)|Maximum Observed Serum Concentration (Cmax) of Atezolizumab in the Global Population, Atezolizumab maximum observed plasma concentration (Cmax; 30 minutes following the end of the atezolizumab infusion) for each respective day., Post-dose Day 1 of Cycle 1 (cycle length = 21 days)|Minimum Observed Serum Concentration (Cmin) of Atezolizumab in the Global Population, Atezolizumab pre-dose plasma concentration (Cmin) for each respective day., Predose on Day 1 of Cycles 1, 3, 4, 8, 16 and 24 (cycle length = 21 days)|Plasma Concentration of Carboplatin in the Global Population, Plasma concentration of carboplatin in the Global population., Predose, before end of infusion, and after end of carboplatin infusion on Day 1 of Cycle 1 and Cycle 3 (cycle = 21 days)|Plasma Concentration of Etoposide in the Global Population, Plasma concentration of etoposide in the Global Population., Predose, before end of infusion, 1 and 4 hours after end of carboplatin infusion on Day 1 of Cycle 1 and Cycle 3 (cycle = 21 days)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,503,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",GO30081|2015-004861-97,2016-06-07,2018-04-24,2022-07-07,2016-05-05,2019-06-13,2023-07-28,"Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, 33901, United States|Florida Hospital, Orlando, Florida, 32804, United States|Florida Cancer Specialists., Saint Petersburg, Florida, 33705, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, 30060, United States|Rush University Medical Center, Chicago, Illinois, 60612-3244, United States|Illinois Cancer Care, Peoria, Illinois, 61615, United States|Cancer Treatment Centers of America - Midwestern Regional Medical Center, Zion, Illinois, 60099, United States|Louisville Oncology, Louisville, Kentucky, 40202, United States|New England Cancer Specialists, Scarborough, Maine, 04074, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, 21237, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, 89169, United States|The Valley Hospital, Paramus, New Jersey, 07652, United States|Broome Oncology - Binghamton, Binghamton, New York, 13905, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Tennessee Oncology Chattanooga, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, 37203, United States|Vanderbilt Medical Center, Nashville, Tennessee, 37232-7610, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Blue Ridge Cancer Care, Roanoke, Virginia, 24014, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|University of Wisconsin, Madison, Wisconsin, 53705, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, 4032, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, 3052, Australia|Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Lungenkrankheiten, Linz, 4020, Austria|Salzburger Landeskliniken; Universitätsklinik für Pneumologie/ Lungenheilkunde, Salzburg, 5020, Austria|Klinik Penzing; Abteilung für Atemwegs- und Lungenkrankheiten, Wien, 1140, Austria|Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie, Wien, 1210, Austria|Santa Casa de Misericordia de Salvador, Salvador, BA, 40050-410, Brazil|Hospital Bruno Born, Lajeado, RS, 95900-000, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-903, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Bradford Hill Centro de Investigaciones Clinicas, Recoleta, 8420383, Chile|OrlandiOncología, Santiago, 7500713, Chile|Beijing Cancer Hospital, Beijing, 100142, China|Jilin Cancer Hospital, Changchun, 132013, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China|Harbin Medical University Cancer Hospital, Harbin, 150081, China|Jiangsu Cancer Hospital, Nanjing City, 211100, China|Fudan University Shanghai Cancer Center, Shanghai City, 200120, China|Zhongshan Hospital Fudan University, Shanghai, 200032, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|Henan Cancer Hospital, Zhengzhou, 450008, China|Fakultni nemocnice Olomouc, Olomouc, 779 00, Czechia|Thomayerova nemocnice, Praha 4 - Krc, 140 59, Czechia|Fakultni nemocnice Na Bulovce, Praha 8, 180 81, Czechia|Institut Bergonie; Oncologie, Bordeaux, 33076, France|Centre Francois Baclesse; Oncologie, Caen, 14076, France|Hopital Calmette; Pneumologie Oncologie Ouest, Lille, 59037, France|Hôpital Nord - AP-HM Marseille#, Marseille, 13915, France|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, 82131, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, 22927, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, 06120, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, 69126, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, 34376, Germany|Sotiria Chest Hospital of Athens, Athens, 11527, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, 145 64, Greece|University Hospital of Patras Medical Oncology, Patras, 265 04, Greece|Semmelweis Egyetem, AOK, Pulmonologiai Klinika, Budapest, 1083, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, 1121, Hungary|Debreceni Egyetem, Klinikai Kozpont, Tudogyogyaszati Klinika, Debrecen, 4032, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, 2045, Hungary|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, 43100, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, 00128, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, 20141, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, 71013, Italy|Azienda Ospedaliera Universitaria Pisana - Ospedale Cisanello; Dipartimento Cardio Toraco Vascolare, Pisa, Toscana, 56124, Italy|Kyushu University Hospital; Respiratory, Fukuoka, 812-8582, Japan|National Hospital Organization Himeji Medical Center, Hyogo, 670-8520, Japan|Kanagawa Cancer Center;Thoracic Oncology, Kanagawa, 241-8515, Japan|University Hospital Kyoto Prefectural University of Medicine,?Pulmonary Medicine, Kyoto, 602-8566, Japan|Sendai Kousei Hospital; Pulmonary Medicine, Miyagi, 980-0873, Japan|Kurashiki Central Hospital; Respiratory Medicine, Okayama, 710-8602, Japan|Kindai University Hospital; Medical Oncology, Osaka, 589-8511, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center; Internal Medicine, Osaka, 591-8555, Japan|Saitama Cancer Center; Thoracic Oncology, Satima, 362-0806, Japan|Shizuoka Cancer Center; Thoracic Oncology, Shizuoka, 411-8777, Japan|Tokyo Metropolitan Komagome Hospital; Thoracic Oncology and Respiratory Medicine, Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR, Respiratory Medicine, Tokyo, 135-8550, Japan|Wakayama Medical University Hospital; Respiratory Medicine and Medical Oncology, Wakayama, 641-8509, Japan|Seoul National University Bundang Hospital, Seongnam-si, 463-707, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), 03100, Mexico|Medical University of Gdansk, Gdansk, 80-952, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, 93-513, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc; Oddzial V Chemioterapii Nowotworow Pluc, Olsztyn, 10-357, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, 05-400, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, 60-569, Poland|Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie; Oncology, Warszawa, 02-781, Poland|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Moskovskaja Oblast, 105229, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Moskovskaja Oblast, 115478, Russian Federation|City Clinical Onc., Sankt-peterburg, Sankt Petersburg, 198255, Russian Federation|Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, 197758, Russian Federation|City Clinical Hospital No. 1, Novosibirsk, 630047, Russian Federation|Clinical Center of Serbia, Belgrade, 11000, Serbia|Clinical Center Nis; Clinic for pulmonary diseases, Nis, 18 000, Serbia|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Sant Andreu de La Barca, Barcelona, 08740, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, 41013, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, 50009, Spain|National Taiwan Uni Hospital; Internal Medicine, Taipei, 100, Taiwan|Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology, Taipei, 112, Taiwan|Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, 333, Taiwan|Royal Devon & Exeter Hospital; Oncology Centre, Exeter, EX2 5DW, United Kingdom|Barts and the London NHS Trust., London, EC1A 7BE, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, SE1 9RT, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, M2O 4BX, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/79/NCT02763579/Prot_SAP_000.pdf"
